The Food and Drug Administration has approved onabotulinumtoxinA, marketed as Botox Cosmetic by Allergan, for a third indication: the temporary improvement in the appearance of “moderate to severe forehead lines associated with frontalis muscle activity” in adults, according to the manufacturer.
The FDA approved the first indication for this product in 2002, namely, the temporary improvement in the appearance of glabellar lines. The second indication – the temporary improvement in the appearance of moderate to severe lateral canthal lines – was approved in 2013.
The company announced the latest approval in a press release on October 3.
